DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA
Health Systems & Preparedness Administration

GOVERNMENT OF THE DISTRICT OF COLUMBIA
MURIEL BOWSER, MAYOR

Government of the District of Columbia
Department of Health

Prescription Drug Monitoring Program Advisory Committee Meeting

2201 Shannon Place SE – Room 290A
WASHINGTON, DC 20020

In-person Meeting

December 10, 2024
10 AM—11:30 AM

AGENDA

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

CALL TO ORDER:

PRESIDING:

COMMITTEE MEMBERSHIP/ATTENDANCE:

ADVISORY COMMITTEE MEMBERS:		
	Aisha Nixon, MPT, CPM, Associate Director	
	Justin Ortique, PharmD, RPh, CPM, Board of Pharmacy Executive Director, Program Manager Pharmaceutical Control Division	
	Sithembile Chithenga, MD, Board of Medicine Executive Director	
	Vito R. DelVento, DVM, MS, Board of Veterinary Medicine Executive Director, Program Manager Animal Services Program	
	Ericka L. Walker, MSW Interim Executive Director Board of Nursing	
	Natalie Kirilichin, MD, MPH, Emergency Medicine Physician	
	Sheri Doyle, MPH, Consumer Member	
	Captain Shawn Rooney, Metropolitan Police Department	
	Sharon Hunt, L.I.C.S.W., Ph.D., State Opioid Treatment Authority	
	Kimberley Heine, Forensic Toxicologist, QA/QC Program Manager	
	Tayiana Reed PharmD, MS, AAHIVP, ACE, RPh, Pharmacist	
PDMP STAFF:	Reginal Bellamy, PharmD, RPh, Supervisory Pharmacist	
	Laurel Alcenat, MBA, Program Specialist	
	Monai Lowe, PharmD, RPh, PDMP Pharmacist	
LEGAL STAFF:	Carla Williams, Esq, Senior Assistant General Counsel, PDMP Attorney Advisor	
VISITORS:		

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

Open Session Agenda
Quorum:

1210-O-01	**Welcome & Introductions** **Chair Report** **Charge of the Committee** The Committee shall convene at least two (2) times per year to advise the Director: (a) On the implementation and evaluation of the Program; (b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances; (c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data; (d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances; (e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and (f) Regarding the design and implementation of educational courses for: (1) Persons who are authorized to access the prescription monitoring information; (2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program; (3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and (4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.	Aisha Nixon
1210-O-02	**Approval of August 2024 PDMP Advisory Committee Meeting Minutes** (a) Minutes from the August 2024 Meeting	

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

1210-O-03

Report from Attorney Advisor

No Report

1210-O-04

Program Updates — Dr. Ortique

(a) PDMP Registration Statistics and Compliance

License Professional	Number of DC Licensed Active Professionals	Number of Registered PDMP Users	Percentage of DC Licensed Active Professionals Registered with the PDMP
Physician	16,275	14,468	89%
Physician Assistant	1,421	1,237	87%
Advanced Practice Nurse	4,371	3,774	86%
Pharmacist	2,299	2,105	92%
Dentist	1,224	1,136	93%
Veterinarian	499	447	90%
Podiatrist	137	124	91%
Optometrist	206	197	96%
Naturopathic Physician	65	53	82%
VA Prescriber	-	357	-
VA Dispenser	-	47	-
Pharmacy Technician or Delegate	1,319	4	0%
Other (Licensing Board Investigator, Law Enforcement, Medical Examiner, Admin)		44	
Total	27,816	23,997	89%

***(b)* Outreach Activity**

Outreach activities since the August 2024 meeting:

Date of Event	Name of Event	Type of Event	Topics Discussed	Audience	Number of Participants
10/25/24	**Improving the Treatment of OUD for Youth**	CE webinar	Opioids	DC prescribers and dispensers	83

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

1210-O-05	**Grant Updates** ***(a) Districtwide Gateway Integration*** A total of 138 health entities have connected to the DC PDMP through Gateway Integration in total since integration began in 2019. **(b)** ***Dashboard DC Gateway Advertisement*** Running 11/12/24 - 12/12/24 **(c)** ***2024 PDMP Harold Rodgers PDMP National Conference, PDMPs: Collaborating to Address the Prescription Drug Crisis*** Occurred August 13-15, 2024, in Herndon, VA DC PDMP staff had the opportunity to network with other PDMP Administrators and learn about other jurisdictions grant related projects	
1210-O-06	**Presentation** DC Prescription Drug Monitoring Program Updates(attached) Presented by: Dr. Monai Lowe, PharmD, RPh, PDMP Pharmacist TFFS MTM Program Presentation Presented by: Tayiana Reed PharmD, MS, AAHIVP, ACE, RPh	Dr. Lowe Dr. Reed
1210-O-07 **Matters for Consideration**	**Action Items** • PDMP Advisory Committee potential recommendation(s) • Potential Future meeting date	Dr. Ortique
1210-O-08	Other news/highlights from Committee members	
Comments from the Public		
Motion to Adjourn the Open Session	Madam Chair, I move that the Committee close the meeting. (Roll Call Vote)	

This concludes the meeting.
Meeting Adjourned at : ____:____

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government opengovoffice@dc.gov

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

DC | HEALTH
Health Regulation & Licensing Administration

WE ARE WASHINGTON DC GOVERNMENT OF THE DISTRICT OF COLUMBIA
MURIEL BOWSER, MAYOR

Government of the District of Columbia
Department of Health

Prescription Drug Monitoring Program
Advisory Committee Meeting

2201 Shannon Place SE – 2ND FLR
WASHINGTON, DC 20020

WebEx Virtual MEETING

August 20, 2024
10:07 AM—11:14 AM

Open Session Minutes

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

CALL TO ORDER: 10:07 am

PRESIDING: Aisha Nixon, MPT, CPM, Associate Director

COMMITTEE MEMBERSHIP/ATTENDANCE:

ADVISORY COMMITTEE MEMBERS:		
	Justin Ortique, PharmD, RPh, CPM, Board of Pharmacy Executive Director, Program Manager Pharmaceutical Control Division	Present
	Aisha Nixon, MPT, CPM, Associate Director Interim Chair	Present
	Sithembile Chithenga, MD, Board of Medicine Executive Director	Present
	Vito R. DelVento, DVM, MS, Board of Veterinary Medicine Executive Director, Program Manager Animal Services Program	Present
	Ericka L. Walker, MSW, Interim Executive Director Board of Nursing	Absent
	Natalie Kirilichin, MD, MPH, Emergency Medicine Physician	Absent
	Sheri Doyle, MPH, Consumer Member	Present
	Captain Shawn Rooney, Metropolitan Police Department	Present
	Sharon Hunt, L.I.C.S.W., Ph.D., State Opioid Treatment Authority	Present
	Kimberley Heine, Forensic Toxicologist, QA/QC Program Manager	Present
	Tayiana Reed PharmD, MS, AAHIVP, ACE, RPh, Pharmacist	Present
	Careen-Joan Franklin, PharmD, RPh, Pharmacist	Present
PDMP STAFF:	Reginal Bellamy, PharmD, RPh, Supervisory Pharmacist	Present
	Laurel Alcenat, MBA, Program Specialist	Present
	Monai Lowe, PharmD, RPh, PDMP Pharmacist	Present
LEGAL STAFF:	Carla Williams, Esq, Senior Assistant General Counsel, PDMP Attorney Advisor	Absent
VISITORS:	Edward Rich, Senior Assistant General Counsel (covering for Carla Williams)	
	Jacob Cooper, Bamboo Health	
	Emily Donohue, Bamboo Health	
	Justin Wood, DEA	
	Latrice Herndon, MS, Executive Director Boards of Allied and Behavioral Health (Covering for Ericka Walker)	

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

Open Session Minutes
Quorum: Yes

0820-O-01	**Welcome & Introductions** **Chair Report** **Charge of the Committee** The Committee shall convene at least two (2) times per year to advise the Director: (a) On the implementation and evaluation of the Program; (b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances; (c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data; (d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances; (e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and (f) Regarding the design and implementation of educational courses for: (1) Persons who are authorized to access the prescription monitoring information; (2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program; (3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and (4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program. . *Ms. Aisha Nixon called the meeting to order and provided a provided a brief overview of the Charge of the committee*	Aisha Nixon
0820-O-02	**Approval of January 2024 PDMP Advisory Committee Meeting Minutes** (a) Minutes from the January 2024 Meeting	

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

	Motion: *Committee member Dr. Ortique made the motion to approve the January 2024 meeting minutes.* ***Seconded by****: Committee member Dr. Chithenga* ***Roll Call Vote:*** • *Dr.Justin Ortique* • *Dr. Sithembile Chithenga* • *Dr. Vito R. DelVento* • *Sheri Doyle* • *Captain Shawn Rooney* • *Dr.Sharon Hunt* • *Kimberley Heine* • *Dr.Tayiana Reed* • *Dr.Careen-Joan Franklin* *Motion carried; minutes approved*	
0820-O-03	**Welcome of the new committee members** *Ms. Nixon welcomed the two new committee members which include herself and Ericka Walker who is serving as the Interim Executive Director Board of Nursing*	

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

0820-O-04

Report from Attorney Advisor

No Report

0820-O-05

Program Updates — Dr. Ortique

(a) PDMP Registration Statistics and Compliance

Licensed Professional	Number of DC Licensed Active Professionals	Number of Registered PDMP Users	Percentage of DC Licensed Active Professionals Registered with the PDMP
Physician	15,839	13965	88%
Physician Assistant	1,335	1,164	87%
Advanced Practice Nurse	3,849	3,536	92%
Pharmacist	2,236	2,085	93.0%
Dentist	1,175	1,097	93%
Veterinarian	472	418	89%
Podiatrist	130	128	98%
Optometrist	197	189	96%
Naturopathic Physician	63	53	84%
VA Prescriber		285	
VA Dispenser		42	
Pharmacy Technician or Delegate	1,232	4	-
Other (Licensing Board Investigator, Law Enforcement, Medical Examiner, Admin)		33	
Total	25,296	22,635	89%

***Current as of 08/2/2024**

(b) Outreach Activity

Outreach activities since the January 2024 meeting:

Date of Event	Name of Event	Type of Event	Topics Discussed	Audience	Number of Participants
2/27/24	**Treatment for Opioid Use Disorder in Carceral Settings**	CE webinar	Opioids	DC prescribers and dispensers	153
6/17/24	**The Pharmacist's Role in Managing Patients with Opioid Use Disorder**	CE Webinar	Opioids	DC prescribers and dispensers	90
8/15/24	**The New Language of Drugs**	CE Webinar	Illicit Opioids	DC prescribers and dispensers	116

0820-O-06

Grant Updates — Dr. Ortique

(a) Districtwide Gateway Integration

A total of 125 health entities have connected to the DC PDMP through Gateway Integration in total since integration began in 2019.

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

	(b) DC Gateway Integration Communication Campaign Spanned 4/29/24-7/1/24 Consisted of 6 emails that were sent to registered AWARxE users who have accessed the DC PDMP in the last year via the web portal only The campaign resulted in 17 new integration requests in DC since the campaign launch ***(c) 2024 PDMP Administrators National Forum*** Occurred May7-9, 2024 in San Antonio, Texas DC PDMP staff had the opportunity to network with other PDMP Administrators and present on our program and grant related projects *Dr. Justin Ortique provided some updates on the PDMP compliance as of 8/2/2024 and the outreach activities since the January 2024 meeting.*	
0820-O-07	**<u>Presentation</u>** DC Prescription Drug Monitoring Program Updates(attached) Bamboo Health Solutions Overview: Overdose Insights and Opioid Treatment Program Reporting Presented by: Jacob Cooper, Vice President of State Accounts, Bamboo Health *Two presentations were done by Dr. Justin Ortique and Jacob Cooper from Bamboo Health. Dr. Ortique highlighted the charge of the committee and then presented on a few potential projects that included an enhancement to the advanced analytics package, potential reporting of OTPs to the DC PDMP as well as fatal and non-fatal overdose notification to prescribers within the DC PDMP. Mr. Cooper provided specific details on how Bamboo Heath can support these projects. He further explained fatal and non-fatal overdose notifications and how Opioid Treatment Program Data could be integrated.*	Dr. Ortique Mr. Cooper
0820-O-08 **Matters for Consideration**	**<u>Action Items</u>** • PDMP Advisory Committee potential recommendation(s) • Potential Future meeting date *Dr. Ortique asked the committee if there were any potential recommendations. The committee did not have any but Ms. Nixon mention that the potential projects that were presented on were great ideas. Furthermore, Dr. Reed stated that she could provide support in areas related to DHCF. Next Dr. Ortique provided the potential next meeting dates and they were determined to be as follows:* • *Tuesday, 12/8/24-In person* • *Tuesday, 4/8/25-Virtual*	Dr. Ortique
0820-O-09	Other news/highlights from Committee members *Ms. Aisha Nixon provided the following updates:* • *DC Health fiscal year for 2025 begins in October.* • *Large number of boards will be going through the renewal period, so as far as compliance for the PMP, the number should go up by next meeting.* • *For licensure renewals, all the licenses issued in June will not expire in*	

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

	two years anymore. It'll expire the last day of the applicant's birth month. • *The Health Occupations Revisions Act has been updated and passed on 7/19/24. This will change how the boards are operating. The boards will go from 19 to 15.* • *Some new professions will be required to register for the PMP.*	
Comments from the Public	*NONE*	
Motion to Adjourn the Open Session	Madam Chair, I move that the Committee close the meeting. *Motion made by: Dr. Justin Ortique* *Seconded by: Dr Tayiana Reed* ***Roll Call Vote:*** • *Aisha Nixon* • *Dr. Justin Ortique* • *Dr. Sithembile Chithenga* • *Dr. Vito R. DelVento* • *Sheri Doyle* • *Captain Shawn Rooney* • *Dr. Sharon Hunt* • *Kimberley Heine* • *Dr. Tayiana Reed* • *Dr. Careen-Joan Franklin* *Motion carried* (Roll Call Vote)	

This concludes the Public Open Session of the meeting

Meeting Adjourned : 11:14 am

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

DC Prescription Drug Monitoring Program (PDMP) Updates

Monai Lowe, PharmD, RPh | December 10, 2024

Copyright 2021 DC Health | Government of the District of Columbia

PDMP Updates

- Dashboard cleanup
- Dispenser Profile cleanup
- Fine Schedule suggested
- Consolidation tab cleared
- “No Specialty” Provider Notice
- Active prescriber identification activated
- Gateway Integration
- Continuing Education training

DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

PDMP Dashboard

Pending Tasks

	Total Pending	Critically Overdue
Patient Request Approvals	0	0
Registration Approvals	0	0
Data Submission Approvals	0	0
Delinquent Submitters	0	0
Insight Reports Processing	0	0

Select a Task

= Critically Overdue

DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

Dispenser Profile Cleanup



DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

Pharmacies

Select a pharmacy to review details about the pharmacy.

Download CSV

DEA	NCPDP	Pharmacy Name	Address	City	State	Zip	Phone Number
DC1210204	0908076	DC Pharmacy	District Way	WASHINGTON	DC	20009	

DC Pharmacy

Save Changes | Delete Pharmacy | Edit Pharmacy

Reporting Requirements

- ○ Exempt
- ○ Default Frequency
- ○ Every [ ] days
- ◉ Daily, except
  - ☐ Sun ☐ Mon ☐ Tue ☐ Wed ☐ Thu
  - ☐ Fri ☑ Sat
- ○ Permanently Closed

Notes

Pharmacy Compliance Dashboard Tableau Settings

Date Exceptions

☑ Zero Reports Required

Pharmacy License #

RX1210204

Pharmacist in Charge

First Name: Required

Last Name:

Email:

DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

Consolidations

Advanced Options | Search using Advanced Options | Search

Requests Processing

Select a request to review details about the request.

Patient First Name	Patient Last Name	Requestor	Requestor Role	Date Requested	Reason
District	Resident	DC Pharmacist	Pharmacist	08/30/2024 7:07 PM	Multiple Patient

DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

Prescriber Reports

- Prescriber Reports provide a summary of practitioners' prescribing of covered substances* over a 6-month period and present an opportunity for self-analysis as it relates to their prescribing of controlled substances
- Reports are sent quarterly
- Notice to >190 providers will be sent on 1/15/2025 to register a "Provider Specialty" to enable receiving Prescriber Reports



DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

Benefits of Prescriber Reports

- Provide prescribing patterns for opioids, buprenorphine, sedatives, and stimulants, along with peer comparisons.
- Identify patients at potentially elevated risk due to overlapping therapies, multiple providers, and higher MME thresholds.
- Indicate patient search activity, including searches performed by authorized delegate(s) made on the prescribers' behalf.



AT-RISK PATIENTS

Dangerous Combination		Multiple Providers	MME Threshold
Benzo + Opioid		Patients with 5 or more Prescribers	Patients Receiving Daily MME >= 90
12 You	85 You + Other Prescribers	25 SAMPLE	83
Benzo + Opioid + Carisoprodol		Patients with 5 or more Pharmacies	Patients Receiving Daily MME >= 120
0 You	0 You + Other Prescribers	40	66

PDMP USAGE

Patient Searches by You	Patient Searches by Your Delegate(s)	Your Total Patient Searches
564 SAMPLE	0	564

DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

Gateway Integration

- Streamlines communication and data transfer
- Providers and dispensers can access PDMP through their EHR or Pharmacy System
- Enhances clinical workflows by eliminating extra login step
- Integration fees covered by DC Health



DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

Gateway Integration



- Total Requests: 238
- In Production: 138
- Awaiting PMPi Approval: 3
- Credentials Sent: 50
- Pending Documents: 37
- On Hold: 5

DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

Continuing Education

- DC PDMP is partnering with Howard University and DACS to offer a Continuing Education training for pharmacists and providers
- CE training will provide dispensers and prescribers with PDMP registration instructions and benefits of using DC PDMP
- After completing the training, participants will have a better understanding of PDMP report data, graphs and risk scores

DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

Findings

- Prescribers register as a requirement for initial licensing or renewal but may not access the database as required by law
- Many prescribers are not aware of the mandatory requirements to query the database and would benefit from formal PDMP training
- Prescribers can successfully prescribe without querying the database, leading to potential increased patient harm
- There is no method currently in place to monitor prescriber access history

DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

Copyright 2021 DC Health | Government of the District of Columbia

Potential Recommendations Based on Findings

- Create a Continuing Education (CE) training program for providers and dispensers registering for PDMP
- Require CE training for initial licensing and licensing renewals for providers and dispensers
  - Incorporate CE training into the required curriculum for relevant health licensing boards
  - Training would fall under the *Public Health Priority* category of "Responsible Opioid Prescribing and Effective Pain Management"

Copyright 2021 DC Health | Government of the District of Columbia

DC | HEALTH

GOVERNMENT OF THE DISTRICT OF COLUMBIA

2201 Shannon Place SE, 2nd Floor, Washington, DC 20020

dchealth.dc.gov

@_DCHealth dchealth DC Health

DHCF FFS MTM Program

Dr. Tayiana J. Reed
Pharmacist, DHCF
Office of the Chief Medical Officer

For Official Government Use Only

What is Medication Therapy Management (MTM)?

Medication therapy management (MTM) services focus on identifying, preventing, and solving drug-related problems to optimize therapeutic outcomes for individual patients.

MTM may be independent of OBRA-90 counseling statue and involves a thorough review of the patient's medications, including medication use history, medical history, and adherence to therapy to identify and resolve drug therapy problems with the patient and/or in collaboration with other health care providers.

MTM Core Elements



For Official Government Use Only

Goal of the FFS MTM Program



For Official Government Use Only

MTM Service Initiatives

Treatment Plan	•Development plan •Document care delivered by pharmacist to primary providers
Comprehensive Reviews	•Medication •Immunization •Prevent medication errors
Monitoring & Evaluation	•Medication response •Safety & Efficacy
Coordination	•Integrating MTM services with other health care services provided to the beneficiary
Education	•Support services •Medication adherence to regimens •Appropriate use of medications

For Official Government Use Only

MTM Beneficiary Eligibility

Must be an outpatient

3 or more qualifying health conditions

Non-adherent

Must be prescribed 10 + meds per month

Must be eligible for DHCF Lock in

MTM Categories Served

FFS Lock-in Beneficiaries

Individual beneficiaries

My Health GPS enrollees

For Official Government Use Only

MTM Eligibility Exclusion

Medicare Part D Beneficiaries

Includes dual eligible

Health Home Program Beneficiaries

Chronic care program contractors currently providing MTM services

MTM Pharmacy Provider Eligibility

- Licensed Pharmacist
  - Unrestricted
  - Malpractice Insurance
  - MTM Education
- NPI required
  - Active
- DC Medicaid Provider
  - Must be enrolled
- Utilize electronic MTM system
  - In accordance with DHCF
- SPA DC-24-008
  - Must meet requirements

DHCF FFS MTM Program Implementation



DHCF FFS MTM Program Workflow



For Official Government Use Only

FFS MTM Program Workflow

Patient files created & identified

PBM Drops in Clinical Que

MTM cases chosen

Chose area of focus for education

Intervention

Program documentation

Recommendations

Medication Plan provided

•In-person or telehealth visit
•14 days & medication list

Follow Up

Schedule additional interventions if multiple chronic disease states are involved

Communicate to provider

Outcome documentation

FFS Program MTM Provider Process Flow

Gather

SOAP approach

- Subjective
- Objective
- Assessment
- Plan

Interpret

Medication –related problems

- Polypharmacy
- Lock –in Candidate

Communicate

Patient

Pharmacist

PCP/ Healthcare Providers

Monitor

Clinical Outcomes

Patient Satisfaction

Professional Satisfaction

Economic Outcomes

MTM FFS Program Reimbursement



For Official Government Use Only

MTM FFS Program Fee Schedule

Service Description	Procedure Code	Rate Effective 7/1/2024
Medication Therapy Management – First encounter; 15 minute unit	99605	$50.00
Medication Therapy Management – follow-up encounter; 15 minute unit	99606	$25.00
Medication Therapy Management – additional 15 minutes	99607	$10.00

MTM State Plan Amendment DC-24-0008

- Approved on 8/2/2024
- Transmittal 24-xxx Pending
  - Provides additional information regarding the requirements and directions for billing.
  - Fee Schedule for reimbursement is complete
  - Provider billing training developed for pharmacist providers

FFS MTM Program's Current Implementation Status

- Procurement of MTM software for eligible pharmacy/pharmacist
  - Pending ETA late spring 2025
  - DHCF will approve eligible pharmacy/pharmacist providers meeting the criteria

- MTM reimbursement for services
  - Currently testing payor sheets for reimbursement at the pharmacy level for one-time MTM at the pharmacy level
  - Pharmacist provider type must be created
    - Pharmacist with collaborative practice vs Pharmacist as a consultant
    - Medical provider number
    - Pharmacist must have the medical system in place to bill as a medical provider

For Official Government Use Only

This Photo by Unknown Author is licensed under CC BY-NC